沙库巴曲缬沙坦治疗高血压患者的临床疗效

Clinical efficacy of sacubitril-valsartan in patients with hypertension

目的探讨沙库巴曲缬沙坦治疗高血压患者的临床效果。方法选取90例高血压患者,随机将其分为两组:对照组(n=45)单纯给予硝苯地平控释片治疗,研究组(n=45)给予沙库巴曲缬沙坦治疗,两组均治疗4周。比较两组临床疗效,以及治疗前后动态血压、血浆抗凝指标水平、血浆炎性因子水平、血管内皮功能指标水平和治疗后不良反应发生情况。结果治疗4周后,研究组的临床疗效优于对照组,24 h平均舒张压低于对照组(85.60±3.56 mmHg比90.22±3.13 mmHg),血浆血小板α-颗粒膜蛋白-140、纤溶酶原激活物抑制物、肿瘤坏死因子-α、白细胞介素-6、C反应蛋白、内皮素水平均低于对照组,血浆组织型纤溶酶原激活物、一氧化氮水平均高于对照组(均P<0.05)。两组治疗期间不良反应发生率差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦治疗高血压患者可有效地降低其舒张压,改善血液黏度、炎症反应和血管内皮功能,安全性高。

Objective To explore the clinical efficacy of sacubitril-valsartan in patients with hypertension.Methods A total of 90 patients with hypertension were selected and randomly divided into two groups:the control group(n=45)was treated with nifedipine controlled-release tablets alone,and the study group(n=45)was treated with sacubitril-valsartan,both groups were treated for 4 weeks.The clinical efficacy,as well as the ambulatory blood pressure,plasma anticoagulant indexes levels,plasma inflammatory factors levels,and vascular endothelial function indexes levels before and after the treatment,and post-treatment incidence of adverse reactions were compared between the two groups.Results After 4 weeks of treatment,as compared with the control group,the study group had better clinical efficacy,lower 24h mean diastolic blood pressure(85.60±3.56 mmHg vs.90.22±3.13 mmHg),lower plasma plateletα-granule membrane protein 140,plasminogen activator inhibitor,tumor necrosis factor-α,interleukin-6,C-reactive protein,and endothelin levels,and higher plasma tissue-type plasminogen activator,and nitric oxide levels(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment(P>0.05).Conclusion In the treatment of patients with hypertension,sacubitril-valsartan can effectively reduce their diastolic blood pressure,improve blood viscosity,inflammatory response,and vascular endothelial function,with a high safety value.